Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Biliary Tract Diseases

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 73 articles:
HTML format
Text format



Single Articles


    January 2019
  1. SCHMIDT T, Schwinge D, Rolvien T, Jeschke A, et al
    Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis.
    J Hepatol. 2019 Jan 11. pii: S0168-8278(19)30016.
    PubMed     Text format     Abstract available


  2. WU F, Wu D, Ren Y, Huang Y, et al
    Generation of hepato-biliary organoids from human induced pluripotent stem cells.
    J Hepatol. 2019 Jan 7. pii: S0168-8278(19)30002.
    PubMed     Text format     Abstract available


  3. TABIBIAN JH, Lindor KD
    NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A nebulous matter.
    J Hepatol. 2019 Jan 6. pii: S0168-8278(18)32623.
    PubMed     Text format    


    December 2018
  4. BAUMEISTER SE, Schlesinger S, Aleksandrova K, Jochem C, et al
    Association of Physical Activity and Risk of Hepatobiliary Cancers: A Multinational Cohort Study.
    J Hepatol. 2018 Dec 21. pii: S0168-8278(18)32633.
    PubMed     Text format     Abstract available


  5. CADAMURO M, Brivio S, Mertens J, Vismara M, et al
    Platelet-Derived Growth Factor-D Enables Liver Myofibroblasts to Promote Tumor Lymphangiogenesis in Cholangiocarcinoma.
    J Hepatol. 2018 Dec 13. pii: S0168-8278(18)32620.
    PubMed     Text format     Abstract available


  6. LEE S, Kim MJ, Kim S, Choi D, et al
    Intraductal Papillary Neoplasm of the Bile Duct: Assessment of Invasive Carcinoma and Long-Term Outcomes using MRI.
    J Hepatol. 2018 Dec 13. pii: S0168-8278(18)32621.
    PubMed     Text format     Abstract available


    November 2018
  7. HIRSCHFIELD GM, Chazouilleres O, Drenth JP, Thorburn D, et al
    Effect of NGM282, a FGF19 analogue, in Primary Sclerosing Cholangitis: a Multicentre, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
    J Hepatol. 2018 Nov 8. pii: S0168-8278(18)32519.
    PubMed     Text format     Abstract available


    October 2018
  8. DE HAAN LR, van Golen RF
    Finding fibroblast growth factor 19 during cholestasis: Does x mark the spot?
    J Hepatol. 2018 Oct 4. pii: S0168-8278(18)32382.
    PubMed     Text format    


    September 2018
  9. TANAKA H, Imasato M, Yamazaki Y, Matsumoto K, et al
    Claudin-3 regulates bile canalicular paracellular barrier and cholesterol gallstone cores formation in mice.
    J Hepatol. 2018 Sep 10. pii: S0168-8278(18)32374.
    PubMed     Text format     Abstract available


  10. RODRIGUES PM, Perugorria MJ, Santos-Laso A, Bujanda L, et al
    Primary biliary cholangitis: a tale of epigenetically-induced secretory failure?
    J Hepatol. 2018 Sep 4. pii: S0168-8278(18)32362.
    PubMed     Text format     Abstract available


    August 2018
  11. CUBERO FJ, Peng J, Liao L, Su H, et al
    Inactivation of Caspase 8 in liver parenchymal cells confers protection against murine obstructive cholestasis.
    J Hepatol. 2018 Aug 22. pii: S0168-8278(18)32297.
    PubMed     Text format     Abstract available


  12. FONTANA RJ, Cirulli ET, Gu J, Kleiner D, et al
    The role of HLA-A *33:01 in Patients with Cholestatic Hepatitis attributed to Terbinafine.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32283.
    PubMed     Text format     Abstract available


    July 2018
  13. PROBERT PM, Leitch AC, Dunn MP, Meyer SK, et al
    Identification of a xenobiotic as a potential environmental trigger in primary biliary cholangitis.
    J Hepatol. 2018 Jul 10. pii: S0168-8278(18)32182.
    PubMed     Text format     Abstract available


  14. PLOTON M, Mazuy C, Gheeraert C, Dubois V, et al
    The Nuclear Bile Acid Receptor FXR is a PKA- and FOXA2-Sensitive Activator of Fasting Hepatic Gluconeogenesis.
    J Hepatol. 2018 Jul 4. pii: S0168-8278(18)32175.
    PubMed     Text format     Abstract available


    June 2018
  15. BRINKERT F, Pukite I, Krebs-Schmitt D, Briem-Richter A, et al
    Allogeneic hematopoietic stem cell transplantation eliminates alloreactive inhibitory antibodies after liver transplantation for bile salt export pump deficiency.
    J Hepatol. 2018 Jun 20. pii: S0168-8278(18)32156.
    PubMed     Text format     Abstract available


  16. YANG L, Mizuochi T, Shivakumar P, Mourya R, et al
    Regulation of Epithelial Injury and Bile Duct Obstruction by NLRP3 and IL-1R1 in Experimental Biliary Atresia.
    J Hepatol. 2018 Jun 7. pii: S0168-8278(18)32123.
    PubMed     Text format     Abstract available


    May 2018
  17. GUICCIARDI ME, Trussoni CE, Krishnan A, Bronk SF, et al
    Macrophages Contribute to the Pathogenesis of Sclerosing Cholangitis in Mice.
    J Hepatol. 2018 May 23. pii: S0168-8278(18)32064.
    PubMed     Text format     Abstract available


  18. PEERAPHATDIT TB, Simonetto DA, Shah VH
    Exploring new treatment paradigms for alcoholic hepatitis by extrapolating from NASH and cholestasis.
    J Hepatol. 2018 May 21. pii: S0168-8278(18)32058.
    PubMed     Text format    


  19. LIU HC, Hu XS, Pang Q, Jin H, et al
    Potential limitations of irradiation stent implantation in unresectable malignant biliary obstruction.
    J Hepatol. 2018 May 15. pii: S0168-8278(18)32021.
    PubMed     Text format    


  20. ZHU HD, Lu J, Teng GJ
    Response to Letter to the Editor on "Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: a multicentre trial".
    J Hepatol. 2018 May 8. pii: S0168-8278(18)32049.
    PubMed     Text format    


    April 2018
  21. POLLHEIMER MJ, Racedo S, Mikels-Vigdal A, Marshall D, et al
    Lysyl oxidase-like protein 2 (LOXL2) Modules Barrier Function in Cholangiocytes In Cholestasis.
    J Hepatol. 2018 Apr 27. pii: S0168-8278(18)32017.
    PubMed     Text format     Abstract available


  22. BRANDL K, Hartmann P, Jih LJ, Pizzo DP, et al
    Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis.
    J Hepatol. 2018 Apr 11. pii: S0168-8278(18)31973.
    PubMed     Text format     Abstract available


    March 2018
  23. SETO WK, Mak SK, Chiu K, Vardhanabhuti V, et al
    Magnetic resonance cholangiogram patterns and clinical profiles of ketamine-related cholangiopathy in drug users.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30164.
    PubMed     Text format     Abstract available


  24. DONG LQ, Shi Y, Ma LJ, Yang LX, et al
    Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30167.
    PubMed     Text format     Abstract available


  25. SCHNEIDER KM, Albers S, Trautwein C
    Role of bile acids in the gut-liver axis.
    J Hepatol. 2018 Mar 5. pii: S0168-8278(17)32450.
    PubMed     Text format    


    February 2018
  26. SHA M, Jeong S, Xia Q
    Antiviral Therapy Improves Survival in patients with HBV infection and Intrahepatic Cholangiocarcinoma undergoing Liver Resection: Novel Concerns.
    J Hepatol. 2018 Feb 20. pii: S0168-8278(18)30122.
    PubMed     Text format    


  27. LI J, Lei Z, Wang K, Shen F, et al
    Reply to "Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection: novel concerns".
    J Hepatol. 2018 Feb 17. pii: S0168-8278(18)30127.
    PubMed     Text format    


  28. KIM AY, Sinn DH, Jeong WK, Kim YK, et al
    Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma.
    J Hepatol. 2018 Feb 2. pii: S0168-8278(18)30071.
    PubMed     Text format     Abstract available


  29. KABASHIMA A, Hirsova P, Bronk SF, Hernandez MC, et al
    Fibroblast Growth Factor Receptor Inhibition induces loss of matrix MCL1 and necrosis in Cholangiocarcinoma.
    J Hepatol. 2018 Feb 2. pii: S0168-8278(18)30073.
    PubMed     Text format     Abstract available


    January 2018
  30. WARDELL CP, Fujita M, Yamada T, Simbolo M, et al
    Genomic Characterization of Biliary Tract Cancers Identifies Driver Genes and Predisposing Mutations.
    J Hepatol. 2018 Jan 19. pii: S0168-8278(18)30021.
    PubMed     Text format     Abstract available


  31. ZHU HD, Guo JH, Huang M, Ji JS, et al
    Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: a multicentre trial.
    J Hepatol. 2018 Jan 10. pii: S0168-8278(18)30012.
    PubMed     Text format     Abstract available


    December 2017
  32. JIROUSKOVA M, Nepomucka K, Oyman-Eyrilmez G, Kalendova A, et al
    Plectin Controls Biliary Tree Architecture and Stability in Cholestasis.
    J Hepatol. 2017 Dec 19. pii: S0168-8278(17)32495.
    PubMed     Text format     Abstract available


    November 2017
  33. LEI Z, Xia Y, Si A, Wang K, et al
    Antiviral Therapy Improves Survival in patients with HBV infection and Intrahepatic Cholangiocarcinoma undergoing Liver Resection.
    J Hepatol. 2017 Nov 16. pii: S0168-8278(17)32438.
    PubMed     Text format     Abstract available


    September 2017
  34. VERHOEVEN CJ, Selten JW, Roest HP, Farid WRR, et al
    Corrigendum to "MicroRNA profiles in graft preservation solution are predictive of ischemic-type biliary lesions after liver transplantation" [J Hepatol 2013; 59:1231-1238].
    J Hepatol. 2017 Sep 27. pii: S0168-8278(17)32279.
    PubMed     Text format    


  35. WU H, Zhang H, Hu LY, Zhang TY, et al
    Is osteopontin a promising prognostic biomarker for cholangiocarcinoma?
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32269.
    PubMed     Text format    


  36. LOOSEN SH, Roderburg C, Luedde T
    Reply to: "Is osteopontin a promising prognostic biomarker for cholangiocarcinoma?"
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32267.
    PubMed     Text format    


    August 2017
  37. THOMPSON RJ
    Sequencing of transporter genes in cholestasis: we are still learning.
    J Hepatol. 2017 Aug 21. pii: S0168-8278(17)32213.
    PubMed     Text format    


  38. KARLSEN TH, Folseraas T, Thorburn D, Vesterhus M, et al
    Primary sclerosing cholangitis - a comprehensive review.
    J Hepatol. 2017 Aug 9. pii: S0168-8278(17)32196.
    PubMed     Text format     Abstract available


    July 2017
  39. DROGE C, Bonus M, Baumann U, Klindt C, et al
    Sequencing of FIC1, BSEP and MDR3 in a large cohort of patients with cholestasis revealed a high number of different genetic variants.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32147.
    PubMed     Text format     Abstract available


  40. ZHANG S, Song X, Cao D, Xu Z, et al
    Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma induced in mice by AKT and Yap co-expression.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32149.
    PubMed     Text format     Abstract available


  41. FICKERT P, Wagner M
    Biliary bile acids in hepatobiliary injury - What is the link?
    J Hepatol. 2017 Jul 13. pii: S0168-8278(17)32008.
    PubMed     Text format     Abstract available


  42. SCHERBER PR, Lammert F, Glanemann M
    Gallstone disease: Optimal timing of treatment.
    J Hepatol. 2017 Jul 13. pii: S0168-8278(17)30214.
    PubMed     Text format    


  43. TRIVEDI PJ, Scalera I, Slaney E, Laing RW, et al
    Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis.
    J Hepatol. 2017 Jul 6. pii: S0168-8278(17)32135.
    PubMed     Text format     Abstract available


  44. CHAZOUILLERES O
    Norursodeoxycholic acid in patients with primary sclerosing cholangitis: a new "urso saga" in the horizon?
    J Hepatol. 2017 Jul 1. pii: S0168-8278(17)32132.
    PubMed     Text format    


    June 2017
  45. LOOSEN SH, Roderburg C, Kauertz KL, Pombeiro I, et al
    Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma.
    J Hepatol. 2017 Jun 28. pii: S0168-8278(17)32121.
    PubMed     Text format     Abstract available


    May 2017
  46. FICKERT P, Hirschfield GM, Denk G, Marschall HU, et al
    norUrsodeoxycholic Acid Improves Cholestasis in Primary Sclerosing Cholangitis.
    J Hepatol. 2017 May 18. pii: S0168-8278(17)32045.
    PubMed     Text format     Abstract available


    April 2017
  47. GRAMMATIKOPOULOS T, Thompson RJ
    Reply to: Doublecortin domain containing protein 2 (DCDC2) genetic variants in primary sclerosing cholangitis.
    J Hepatol. 2017 Apr 28. pii: S0168-8278(17)30253.
    PubMed     Text format    


  48. CHEUNG AC, Juran BD, Moore RM, LaRusso NF, et al
    Doublecortin domain containing protein 2 (DCDC2) genetic variants in primary sclerosing cholangitis.
    J Hepatol. 2017 Apr 28. pii: S0168-8278(17)30254.
    PubMed     Text format    


  49. HIRSCHFIELD GM, Beuers U, Corpechot C, Invernizzi P, et al
    EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.
    J Hepatol. 2017 Apr 17. pii: S0168-8278(17)30186.
    PubMed     Text format     Abstract available



  50. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline.
    J Hepatol. 2017 Apr 13. pii: S0168-8278(17)30108.
    PubMed     Text format     Abstract available


  51. SEIDEL RA, Claudel T, Schleser FA, Ojha NK, et al
    Impact of higher-order heme degradation products on hepatic function and hemodynamics.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30208.
    PubMed     Text format     Abstract available


  52. RIZVI S, Gores GJ
    Emerging Molecular Therapeutic Targets for Cholangiocarcinoma.
    J Hepatol. 2017 Apr 4. pii: S0168-8278(17)30197.
    PubMed     Text format     Abstract available


    March 2017
  53. JULICH-HAERTEL H, Urban SK, Krawczyk M, Willms A, et al
    Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma.
    J Hepatol. 2017 Mar 3. pii: S0168-8278(17)30123.
    PubMed     Text format     Abstract available


  54. TACKE F
    Targeting hepatic macrophages to treat liver diseases.
    J Hepatol. 2017 Mar 3. pii: S0168-8278(17)30125.
    PubMed     Text format     Abstract available


    February 2017
  55. ORNTOFT NW, Munk OL, Frisch K, Ott P, et al
    Hepatobiliary transport kinetics of the conjugated bile acid tracer 11C-CSar quantified in healthy humans and patients by Positrion Emission Tomography (PET).
    J Hepatol. 2017 Feb 26. pii: S0168-8278(17)30120.
    PubMed     Text format     Abstract available


  56. KRONES E, Eller K, Pollheimer MJ, Racedo S, et al
    NorUrsodeoxycholic Acid Ameliorates Cholemic Nephropathy in Bile Duct Ligated Mice.
    J Hepatol. 2017 Feb 24. pii: S0168-8278(17)30116.
    PubMed     Text format     Abstract available


  57. MERINO-AZPITARTE M, Lozano E, Perugorria MJ, Esparza-Baquer A, et al
    SOX17 Regulates Cholangiocyte Differentiation and Acts as a Tumor Suppressor in Cholangiocarcinoma.
    J Hepatol. 2017 Feb 22. pii: S0168-8278(17)30114.
    PubMed     Text format     Abstract available


  58. NAKAGAWA R, Muroyama R, Saeki C, Goto K, et al
    miR-425 regulates inflammatory cytokine production in CD4+ T cells via N-Ras upregulation in primary biliary cholangitis.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30066.
    PubMed     Text format     Abstract available


  59. GUPTA K, Li Q, Fan JJ, Fong EL, et al
    Actomyosin Contractility Drives Bile Regurgitation as an Early Response During Obstructive Cholestasis.
    J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30061.
    PubMed     Text format     Abstract available


  60. VESTERHUS M, Holm A, Hov JR, Nygard S, et al
    Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis.
    J Hepatol. 2017 Feb 1. pii: S0168-8278(17)30052.
    PubMed     Text format     Abstract available


    January 2017
  61. MOEINI A, Sia D, Zhang Z, Camprecios G, et al
    Mixed hepatocellular-cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity.
    J Hepatol. 2017 Jan 23. pii: S0168-8278(17)30014.
    PubMed     Text format     Abstract available


  62. HANLEY J, Kumar Dhar D, Mazzacuva F, Fiadeiro R, et al
    Vps33b is Crucial for Structural and Functional Hepatocyte Polarity.
    J Hepatol. 2017 Jan 9. pii: S0168-8278(17)30005.
    PubMed     Text format     Abstract available


  63. EKSTEEN B, Heatherington J, Oshiomogo J, Panaccione R, et al
    Retraction notice to: PS124-Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease [J Hepatol 64 (2016) S199].
    J Hepatol. 2017;66:254.
    PubMed     Text format    


    December 2016
  64. SCHWINGE D, von Haxthausen F, Quaas A, Carambia A, et al
    Dysfunction of hepatic regulatory T cells in experimental sclerosing cholangitis is related with IL-12 signaling.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30705.
    PubMed     Text format     Abstract available


    November 2016
  65. MONTE MJ, Alonso-Pena M, Briz O, Herraez E, et al
    ACOX2 deficiency: An inborn error of bile acid synthesis identified in an adolescent with persistent hypertransaminasemia.
    J Hepatol. 2016 Nov 21. pii: S0168-8278(16)30652.
    PubMed     Text format     Abstract available


  66. LOFFLER MW, Chandran PA, Laske K, Schroeder C, et al
    Erratum to "Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient".
    J Hepatol. 2016 Nov 15. pii: S0168-8278(16)30613.
    PubMed     Text format    


    October 2016
  67. RICKE J, Seidensticker M
    Molecular imaging and liver function assessment by hepatobiliary MRI.
    J Hepatol. 2016 Oct 8. pii: S0168-8278(16)30566.
    PubMed     Text format    


  68. SCHRUMPF E, Kummen M, Valestrand L, Greiner TU, et al
    The gut microbiota contributes to a mouse model of spontaneous bile duct inflammation.
    J Hepatol. 2016 Oct 5. pii: S0168-8278(16)30559.
    PubMed     Text format     Abstract available


  69. FICKERT P
    Bad memories from the gut may cause nightmares for the bile ducts - "Nothing fixes a thing so intensely in the memory as the wish to forget it.": Editorial for: "Gut and liver T cells of common clonal origin are detected in primary sclerosing cholangi
    J Hepatol. 2016 Oct 1. pii: S0168-8278(16)30543.
    PubMed     Text format    


    September 2016
  70. VAQUERO J, Guedj N, Claperon A, Ho-Bouldoires TH, et al
    Epithelial-mesenchymal transition in cholangiocarcinoma: from clinical evidence to regulatory networks.
    J Hepatol. 2016 Sep 26. pii: S0168-8278(16)30537.
    PubMed     Text format     Abstract available


  71. HENRIKSEN EK, Jorgensen KK, Kaveh F, Holm K, et al
    Gut and liver T cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease.
    J Hepatol. 2016 Sep 16. pii: S0168-8278(16)30503.
    PubMed     Text format     Abstract available


    April 2016
  72. WESTBROOK RH, Dusheiko G, Williamson C
    Pregnancy and liver disease.
    J Hepatol. 2016;64:933-45.
    PubMed     Text format     Abstract available


    January 2016
  73. EKSTEEN B, Heatherington J, Oshiomogo J, Panaccione R, et al
    RETRACTED: Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (Psc) in Individuals with Inflammatory Bowel Disease.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Biliary Tract Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: